Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.

Imperial College at Hammersmith Hospital, London, United Kingdom.
Journal of Clinical Oncology (Impact Factor: 17.88). 03/2010; 28(11):1888-95. DOI: 10.1200/JCO.2009.26.7757
Source: PubMed

ABSTRACT PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is curative therapy for chronic myeloid leukemia (CML), but its long-term outcomes are not well described. We studied the long-term outcomes of CML patients in first chronic phase who receive an allogeneic HCT. PATIENTS AND METHODS Our study included 2,444 patients who received myeloablative HCT for CML in first chronic phase between 1978 and 1998 and survived in continuous complete remission for at least 5 years (median follow-up, 11 years; range, 5 to 25 years). Donor sources were human leukocyte antigen-matched siblings in 1,692 patients, unrelated donors in 639 patients, and other related donors in 113 patients. RESULTS Overall survival rates at 15 years were 88% (95% CI, 86% to 90%) for sibling HCT and 87% (95% CI, 83% to 90%) for unrelated donor HCT. Corresponding cumulative incidences of relapse were 8% (95% CI, 7% to 10%) and 2% (95% CI, 1% to 4%), respectively. The latest relapse was reported 18 years post-HCT. In multivariable analyses, history of chronic graft-versus-host disease increased risks of late overall mortality and nonrelapse mortality but reduced risks of relapse. In comparison with age-, race-, and sex-adjusted normal populations, the mortality of HCT recipients was significantly higher until 14 years post-HCT; thereafter, mortality rates were similar to those of the general population (relative mortality ratio at 15 years, 2.3; 95% CI, 0 to 4.9). CONCLUSION Recipients of allogeneic HCT for CML in first chronic phase who remain in remission for at least 5 years have favorable subsequent long-term survival, and their mortality rates eventually approach those of the general population.

  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT The therapeutic landscape of chronic-phase chronic myeloid leukemia (CP-CML) has truly been revolutionized with the advent of BCR-ABL1 tyrosine-kinase inhibitor (TKI) therapy. First-line therapy with the TKI imatinib has produced high rates of remissions among treatment-naive patients, as well as patients previously treated with interferon. However, imatinib resistance and intolerance remain significant clinical challenges. Dasatinib, nilotinib, bosutinib, and ponatinib are more recently developed TKIs that have been shown to be very effective as second- or later-line treatment for CML after imatinib failure. Dasatinib and nilotinib are also approved for use in newly diagnosed patients with CP-CML, and produce faster responses when compared with first-line imatinib. Resistance or intolerance can occur with any of the currently available TKIs, necessitating a change to an alternate TKI or consideration of allogeneic hematopoietic stem cell transplant. Treatment options and outcomes for patients whose first-line therapy has failed are reviewed in depth in this article.
    Leukemia and Lymphoma 06/2014; · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract With improved outcome for patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), treatment discontinuation has become increasingly attractive to patients. We analyzed the outcomes of patients who chose to discontinue TKI therapy regardless of their ongoing response. Thirty-five patients with chronic phase CML discontinued TKI in complete cytogenetic response. Of them 51% discontinued due to adverse effects, 23% long CMR (>5 years), 9% pregnancy, and 17% due to financial problems. After TKI discontinuation, patients were followed for a median of 16 months. Among 27 patients (77%) who discontinued TKI in CMR, 11 (41%) had molecular relapse after a median of 3.5 months. In univariate analysis we observed patients with ≥ 64 months of CMR before TKI discontinuation had superior cumulative proportions of sustained CMR and MMR at 12 months after discontinuation 88.9% vs. 45.5% (p=0.02) and 100% vs. 75% (p=0.05), respectively. Patients treated with high dose imatinib or second generation TKIs had higher cumulative proportion of sustained MMR at 12 months after discontinuation than patients treated with standard dose imatinib 100% vs. 72.2% (p=0.03), respectively. Of the 5 patients who stopped TKI in MR(4.5) one lost cytogenetic response. All 3 patients who discontinued TKI in MMR lost cytogenetic response; one progressed to accelerated phase. Thirteen patients (37%) re-started TKIs after loss of response; 11 improved their response, and 2 are too early to assess. Treatment discontinuation can lead to sustained CMR in some patients, but risk of relapse is higher if patients discontinue not in CMR.
    Leukemia & lymphoma 08/2013; · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Small clinical studies have found that patients with idealized response to imatinib can sustain long-lasting responses after treatment discontinuation, suggesting that these patients may be effectively "cured" of chronic myeloid leukemia (CML). Treatment discontinuation is not presently considered routine practice and is not recommended outside the context of clinical research. Many questions remain regarding "cure" in CML: how "cure" is defined, what factors predict successful treatment discontinuation, and what management strategies are the most appropriate post-discontinuation, especially when molecular relapse occurs. This review addresses these issues and discusses the current knowledge regarding treatment discontinuation and a potential for "cure" of CML.
    Leukemia research 09/2013; · 2.36 Impact Factor


Available from